
Commentary|Videos|June 5, 2024
Dr Garrido-Castro on Sacituzumab Govitecan With or Without Pembrolizumab in Metastatic HR+/HER2– Breast Cancer
Author(s)Ana Christina Garrido-Castro, MD
Ana Christina Garrido-Castro, MD, on sacituzumab govitecan with/without pembrolizumab in metastatic hormone receptor–positive, HER2-negative breast cancer.
Advertisement
Ana Christina Garrido-Castro, MD, medical oncologist, co-director, Triple-Negative Breast Cancer Working Group, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses findings from the phase 2 SACI-IO HR+ trial (NCT04448886) evaluating sacituzumab govitecan-hziy (Trodelvy) with or without pembrolizumab (Keytruda) in patients with metastatic hormone receptor–positive, HER2-negative breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5




































